Unlicensed and off-label drug use in children - Implications for safety

被引:159
|
作者
Choonara, I [1 ]
Conroy, S [1 ]
机构
[1] Univ Nottingham, Acad Div Child Hlth, Derbyshire Childrens Hosp, Derby DE22 3NE, England
关键词
D O I
10.2165/00002018-200225010-00001
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
A significant number of children receive either an unlicensed or an off-label drug during their stay in hospital. Studies throughout Europe have shown that at least one-third of children in hospital and up to 90% of neonates in a neonatal intensive care unit receive such drug prescriptions. The medicines that are most frequently used off-label include analgesics, antibiotics and bronchodilators. The purpose of licensing a drug is to ensure safety, efficacy and quality. If a drug is used in a different manner, one would expect a greater risk of toxicity. Only three studies have commented on the risk of toxicity in relation to unlicensed or off label drug use. Only one of these three studies prospectively tried to evaluate the risk associated with off-label and unlicensed drug prescription. This study suggested that the percentage of unlicensed and off-label drug use was significantly associated with the risk of an adverse drug reaction. Two studies looking at adverse drug reactions suggest that there is a greater risk of a severe adverse drug reaction occurring in association with the off-label or unlicensed use of drugs. One study found that five out of eight severe adverse drug reactions were associated with the off-label use of a medicine. The other study found that 14 of 19 drug prescriptions associated with 17 severe adverse drug reactions were either unlicensed or off-label. The risk of prescribing off-label and unlicensed drugs in children is not clear from the limited data available.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 50 条
  • [1] Unlicensed and Off-Label Drug Use in ChildrenImplications for Safety
    Imti Choonara
    Sharon Conroy
    [J]. Drug Safety, 2002, 25 : 1 - 5
  • [2] Off-label and unlicensed drug use in children population
    Moulis, Florence
    Durrieu, Genevieve
    Lapeyre-Mestre, Maryse
    [J]. THERAPIE, 2018, 73 (02): : 135 - 149
  • [3] Off-label and unlicensed drug use in children Comment
    Kimland, E.
    [J]. PAEDIATRICS AND INTERNATIONAL CHILD HEALTH, 2014, 34 (01) : 1 - 2
  • [4] Compassionate therapy in children: Unlicensed and off-label drug use
    Muro-Brussi, M.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 99 : 14 - 15
  • [5] Unlicensed and off-label drug use in hospitalized children in Russia
    Ratchina, Svetlana
    Belokhvostova, Anna
    Konovalova, Ludmila
    Zharkova, Ludmila
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S266 - S266
  • [6] The use of unlicensed and off-label medicines in children
    Conroy, S.
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2009, 61 : A145 - A145
  • [7] Safety and Efficacy of Off-label and Unlicensed Medicines in Children
    Lee, Ji-Hyun
    Byon, Hyo-Jin
    Choi, Seungeun
    Jang, Young-Eun
    Kim, Eun-Hee
    Kim, Jin-Tae
    Kim, Hee-Soo
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2018, 33 (37)
  • [8] Unlicensed and off-label drug use: Issues and recommendations
    Conroy S.
    [J]. Pediatric Drugs, 2002, 4 (6) : 353 - 359
  • [9] Risk factors for unlicensed and off-label drug use in children outside the hospital
    Schirm, E
    Tobi, H
    de Jong-van den Berg, LTW
    [J]. PEDIATRICS, 2003, 111 (02) : 291 - 295
  • [10] Manufacturers' promotion of off-label drug use: implications for drug safety
    Zieve, Allison
    Carome, Michael A.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2016, 15 (09) : 1149 - 1151